BIO-Europe Spring® 2016: Sprint Bioscience on preclinical focus and plans for long-term independence

May 10, 2016
Anne-Marie Wenthzel, VP of business development at Sprint Bioscience, chats with Sten Stovall during the BIO-Europe Spring partnering conference in Stockholm, Sweden, about the company's business model and preclinical checklist for success. She explains Sprint's long-term business plan to be a sustainable independent drug developer, why the company chose to go public in 2014 and what we should expect to see from Sprint in the future.
Previous Video
BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?
BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?

Dr. Thomas Zioncheck, senior director of Genentech Partnering (a unit of Roche subsidiary Genentech Inc.), ...

Next Video
BIO-Europe Spring® 2016: Accord Research on perks of business in the Czech Republic
BIO-Europe Spring® 2016: Accord Research on perks of business in the Czech Republic

After a couple of quiet years working on a large project, Czech Republic-based contract research organizati...